• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Life Sciences | News, Analysis, Insights - HIT Consultant

Oxford Cannabinoid Technologies Achieves “Proof of Concept” for AI-Powered Drug Discovery

by Fred Pennic 11/11/2024 Leave a Comment

Oxford Cannabinoid Technologies Achieves "Proof of Concept" for AI-Powered Drug Discovery

What You Should Know:  - Oxford Cannabinoid Technologies (OCT) has announced a significant milestone in its drug discovery program: the successful "proof of concept" of its AI-enabled drug discovery asset.  - Developed in collaboration with New York-based tech consultancy Hypatia AI, this cutting-edge tool promises to accelerate OCT's research and development of non-addictive pain medications. Accelerating Drug Discovery with AI Hypatia AI's technology acts as an "endlessly
Read More

American Brain Foundation Launches $10M Neuroinflammation Research Initiative

by Syed Hamza Sohail 11/08/2024 Leave a Comment

American Brain Foundation Launches $10M Neuroinflammation Research Initiative

What You Should Know: -  The American Brain Foundation has launched a $10 million cross-disciplinary research initiative that transcends traditional research and philanthropy boundaries by bringing together nonprofit organizations, pharmaceutical and biotech investors, philanthropists, and researchers. - The initiative will provide funding for research by top neuroscientists to investigate the role of neuroinflammation in a wide range of brain diseases, both neurologic and psychiatric,
Read More

Japan’s National Cancer Center Selects Paradigm for Nationwide Clinical Trial Network

by Fred Pennic 11/06/2024 Leave a Comment

Japan's National Cancer Center Selects Paradigm for Nationwide Clinical Trial Network

What You Should Know:  - A new cancer treatment and research era is dawning in Japan with the launch of LC-SCRUM-CD (Lung Cancer Genome Screening Project for Individualized Medicine - Clinical Development).  - The nationwide clinical trial network is a collaborative effort between the National Cancer Center (NCC), Precision Medicine Asia Co., Ltd. (PREMIA), and Paradigm Health Inc. (Paradigm).  Building on LC-SCRUM-Asia's Foundation LC-SCRUM-CD expands upon the existing
Read More

PrognomiQ Raises $34M to Advance Multi-Omics Early Detection Test for Lung Cancer

by Fred Pennic 11/05/2024 Leave a Comment

PrognomiQ Raises $34M to Advance Multi-Omics Early Detection Test for Lung Cancer

What You Should Know:  - PrognomiQ, a healthcare company pioneering multi-omics approaches to disease detection, has secured $34M in Series D funding led by Seer, Inc., with participation from a new strategic investor and existing investors including Catalio Capital Management, aMoon, Invus and Bruker.   - The funding brings PrognomiQ’s total funding to more than $135M and will accelerate the development of PrognomiQ's early detection test for lung cancer. Enhancing Lung
Read More

Evogene and Google Cloud Partner to Develop AI Foundation Model for Drug Discovery

by Syed Hamza Sohail 11/01/2024 Leave a Comment

Evogene and Google Cloud Partner to Develop AI Foundation Model for Drug Discovery

What You Should Know: - Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced a collaboration with Google Cloud to develop a cutting-edge foundation model for generative small molecule de novo design, propelling Evogene’s ChemPass AI tech-engine to new levels of innovation. - ChemPass AI is a computational technology platform that directs and accelerates the discovery
Read More

Starget Pharma Secures $5.1M for AI-Powered Targeted Radiotherapy for Cancer

by Fred Pennic 10/31/2024 Leave a Comment

What You Should Know:  - Starget Pharma, an innovative startup specializing in precision cancer diagnostics and targeted radiotherapy, has secured $5.1M in funding from Cancer Focus, a fund established in collaboration with the renowned MD Anderson Cancer Center.  - The investment will support Starget Pharma's upcoming clinical trial for treating advanced metastatic cancers, including sarcomas, neuroendocrine tumors, melanoma, and liver cancer. Revolutionizing Cancer Treatment
Read More

Accenture Invests in 1910 Genetics to Accelerate AI-Powered Drug Discovery

by Fred Pennic 10/31/2024 Leave a Comment

Accenture Invests in 1910 Genetics to Accelerate AI-Powered Drug Discovery

What You Should Know:  - Accenture has made a strategic investment, through Accenture Ventures, in 1910 Genetics, a biotechnology company revolutionizing drug discovery with its AI-powered platform. Terms of the investment were not disclosed. - The strategic collaboration will combine Accenture's expertise in scaling AI solutions with 1910 Genetics' innovative technology to help biopharmaceutical companies accelerate drug development, reduce costs, and deliver more effective therapies
Read More

Ready to Change Your Pharmacy Strategy? It’s Time for Analytics, Data, and AI

by Kayt Leonard, Global Health Care Strategic Advisor at SAS 10/31/2024 Leave a Comment

Ready to Change Your Pharmacy Strategy? It’s Time for Analytics, Data, and AI

When you think about pharmacy, the first thing that comes to mind is data, right?  Admittedly, it’s not my first thought either. But for organizations that are chasing after stronger, more integrated strategies to deliver care to patients, a pharmacy data strategy – and pharmacy partnership with analytics platforms – is often the first area of focus to drive change and deliver stronger outcomes. The idea of “pharmacy” isn’t just in the terms of where a patient picks up their
Read More

H1 Expands Trial Landscape Platform with UK Diversity Data and AI-Powered Site Rescue

by Fred Pennic 10/31/2024 Leave a Comment

H1 Expands Trial Landscape Platform with UK Diversity Data and AI-Powered Site Rescue

What You Should Know:  - H1, a provider of healthcare data and analytics, has announced significant enhancements to its Trial Landscape platform.  - These updates include the integration of diversity data for over 34 million patients in England and the launch of an AI-powered Site Rescue functionality, both designed to accelerate equitable clinical trials and improve research outcomes. Addressing Diversity in Clinical Trials Diversity, equity, and inclusion (DEI) are
Read More

Medable Partners with Google Cloud to Accelerate Clinical Trials

by Fred Pennic 10/30/2024 Leave a Comment

Medable Partners with Google Cloud to Accelerate Clinical Trials

What You Should Know:  - Medable Inc., a provider of decentralized and hybrid clinical trial solutions, is collaborating with Google Cloud to make its Digital and Decentralized Clinical Trial Platform available on the Google Cloud Marketplace.  - The strategic partnership will empower life sciences companies to accelerate clinical development by leveraging Google Cloud's cutting-edge infrastructure and AI capabilities. Streamlining Clinical Trials with Medable and Google
Read More

  • Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 9
  • Go to page 10
  • Go to page 11
  • Go to page 12
  • Go to page 13
  • Interim pages omitted …
  • Go to page 85
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |